Endeavor BioMedicines revealed positive Phase 2 study results for ENV-101 in January, showing promise in improving lung function decline in idiopathic pulmonary fibrosis patients. They plan to conduct further studies with the new funding.
Founders
John Hood
Company Description
Endeavor BioMedicines develops new treatments targeting the underlying causes of pulmonary fibrosis.